Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuki Ichikawa

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
Nutrition Research (New York, N.Y.)|March 17, 2009
A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinomaShigeyuki Takeshita, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Diagnostics (Basel, Switzerland)|January 28, 2026
Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional StudyTatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, et al.
International Journal of Oncology|July 26, 2006
DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cellsDaisuke Nishimura, Hiroki Ishikawa, Kojiro Matsumoto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2007
Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosisHisamitsu Miyaaki, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Cancer|June 5, 2003
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionKazuyuki Ohata, Keisuke Hamasaki, Kan Toriyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 19, 2025
Plasma Vascular Endothelial Growth Factor-A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and BevacizumabKazuaki Tajima, Satoshi Miuma, Ryu Sasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver diseaseTatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, et al.
Journal of Gastroenterology|November 1, 2011
Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cellsShigeyuki Takeshita, Tatsuki Ichikawa, Naota Taura, et al.
Oncology Reports|April 8, 2010
Differences in prognostic factors according to viral status in patients with hepatocellular carcinomaHiroshi Akahoshi, Naota Taura, Tatsuki Ichikawa, et al.
Journal of Gastroenterology|May 14, 2009
Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathwayAzusa Matsumoto, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
Nutrition Research (New York, N.Y.)|March 17, 2009
A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinomaShigeyuki Takeshita, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Diagnostics (Basel, Switzerland)|January 28, 2026
Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional StudyTatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, et al.
International Journal of Oncology|July 26, 2006
DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cellsDaisuke Nishimura, Hiroki Ishikawa, Kojiro Matsumoto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2007
Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosisHisamitsu Miyaaki, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Cancer|June 5, 2003
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionKazuyuki Ohata, Keisuke Hamasaki, Kan Toriyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 19, 2025
Plasma Vascular Endothelial Growth Factor-A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and BevacizumabKazuaki Tajima, Satoshi Miuma, Ryu Sasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver diseaseTatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, et al.
Journal of Gastroenterology|November 1, 2011
Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cellsShigeyuki Takeshita, Tatsuki Ichikawa, Naota Taura, et al.
Oncology Reports|April 8, 2010
Differences in prognostic factors according to viral status in patients with hepatocellular carcinomaHiroshi Akahoshi, Naota Taura, Tatsuki Ichikawa, et al.
Journal of Gastroenterology|May 14, 2009
Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathwayAzusa Matsumoto, Tatsuki Ichikawa, Kazuhiko Nakao, et al.
Pageof 15